Where does Frank Torti work?

Frank Torti is Board director at Immunovant.

What check size does Frank Torti write?

Frank Torti typically writes checks of $10K – $50K.

Where did Frank Torti go to school?

Frank Torti studied at Harvard Business School (MBA); UNC School of Medicine (MD).

Frank Torti

Board director at Immunovant · Former Partner at New Enterprise Associates (NEA)

United States

Writes $10K – $50K checks · typically $25K

Find your path to Frank

33 people in our graph can introduce you to Frank.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Anup Singh to introduce you to Frank

You →Anup · together at Priovant Therapeutics (2025–2026) →Frank

Ask Jamie Chen to introduce you to Frank

You →Jamie · 2 people · together at Immunovant →Frank

Ask Sam Okafor to introduce you to Frank

You →Sam · 9 people · together at Roivant →Frank

Your email: the people you already email who know Frank
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Frank
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

Frank Torti is the Vant Chair and President at Roivant Sciences (NASDAQ: ROIV) and Executive Chairman at Immunovant (NASDAQ: IMVT) and Priovant, and previously served as founding CEO and Chairman of Telavant until its sale to Roche. Before Roivant, he was a partner at New Enterprise Associates and worked at the Duke University Center for Clinical & Genetic Economics on clinical trials research and economic evaluations. He holds a BA from the University of North Carolina, an MD from the University of North Carolina School of Medicine, and an MBA from Harvard Business School.

Board director at Immunovant

Intro paths

→

In turn, Frank can intro founders to Immunovant's investors below.

Immunovant's investors · 1

Altium CapitalNew York · since 2025

Experience

Roivant SciencesVant Chair & Presidentcurrent2018 — present
ImmunovantExecutive Chairmancurrent2021 — present
Priovant TherapeuticsExecutive Chairmancurrent2022 — present
Telavant (Acquired by Roche for $7.25B)CEO and Chairman2022 — 2024
New Enterprise AssociatesPartner2007 — 2018San Francisco Bay Area

Frequently asked questions

Who is Frank Torti?: Frank Torti is the Vant Chair and President at Roivant Sciences (NASDAQ: ROIV) and Executive Chairman at Immunovant (NASDAQ: IMVT) and Priovant, and previously served as founding CEO and Chairman of Telavant until its sale to Roche. Before Roivant, he was a partner at New Enterprise Associates and worked at the Duke University Center for Clinical & Genetic Economics on clinical trials research and economic evaluations. He holds a BA from the University of North Carolina, an MD from the University of North Carolina School of Medicine, and an MBA from Harvard Business School.
Where does Frank Torti work?: Frank Torti is Board director at Immunovant.
What check size does Frank Torti write?: Frank Torti typically writes checks of $10K – $50K.
Where did Frank Torti go to school?: Frank Torti studied at Harvard Business School (MBA); UNC School of Medicine (MD).